---
title: "Insider Selling: Sarepta Therapeutics, Inc. (NASDAQ:SRPT) CFO Sells 5,985 Shares of Stock"
description: "Sarepta Therapeutics CFO Ian Michael Estepan sold 5,985 shares of the company's stock at an average price of $4.36, totaling $26,099.60. After the sale, he owns 33,946 shares valued at approximately $"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/213368970.md"
published_at: "2024-09-04T01:18:29.000Z"
---

# Insider Selling: Sarepta Therapeutics, Inc. (NASDAQ:SRPT) CFO Sells 5,985 Shares of Stock

> Sarepta Therapeutics CFO Ian Michael Estepan sold 5,985 shares of the company's stock at an average price of $4.36, totaling $26,099.60. After the sale, he owns 33,946 shares valued at approximately $162,822.56. The transaction was disclosed in a SEC filing. The company's stock price decreased by 0.5% to $11.10 during mid-day trading.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Get Free Report) CFO Ian Michael Estepan sold 5,985 shares of the business's stock in a transaction on Friday, August 30th. The shares were sold at an average price of $137.36, for a total transaction of $822,099.60. Following the sale, the chief financial officer now directly owns 33,946 shares in the company, valued at approximately $4,662,822.56. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Get **Sarepta Therapeutics** alerts:

## Sarepta Therapeutics Trading Down 0.5 %

-   This Early-Stage Biotech Stock Is Up 400% — Should You Buy Now?

Sarepta Therapeutics stock traded down $0.68 during mid-day trading on Tuesday, hitting $135.10. The company's stock had a trading volume of 1,186,505 shares, compared to its average volume of 1,346,542. The company has a debt-to-equity ratio of 1.05, a current ratio of 3.90 and a quick ratio of 3.19. The stock has a market cap of $12.77 billion, a price-to-earnings ratio of 1,234.36 and a beta of 0.89. The business has a 50 day moving average price of $144.46 and a 200-day moving average price of $133.13. Sarepta Therapeutics, Inc. has a 12 month low of $55.25 and a 12 month high of $173.25.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last issued its quarterly earnings data on Wednesday, August 7th. The biotechnology company reported $0.07 EPS for the quarter, beating the consensus estimate of $0.01 by $0.06. The firm had revenue of $362.90 million during the quarter, compared to the consensus estimate of $394.38 million. Sarepta Therapeutics had a net margin of 3.14% and a return on equity of 5.32%. The company's quarterly revenue was up 38.9% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.27) earnings per share. As a group, analysts forecast that Sarepta Therapeutics, Inc. will post 1.47 EPS for the current year.

## Hedge Funds Weigh In On Sarepta Therapeutics

-   Sarepta Therapeutics Stock Soars on FDA Approval

Several hedge funds and other institutional investors have recently modified their holdings of SRPT. Capital International Investors raised its stake in shares of Sarepta Therapeutics by 160.0% during the fourth quarter. Capital International Investors now owns 4,741,485 shares of the biotechnology company's stock valued at $457,221,000 after acquiring an additional 2,917,797 shares during the last quarter. Farallon Capital Management LLC raised its stake in Sarepta Therapeutics by 102.8% in the first quarter. Farallon Capital Management LLC now owns 2,453,500 shares of the biotechnology company's stock worth $317,630,000 after buying an additional 1,243,427 shares in the last quarter. Norges Bank bought a new position in Sarepta Therapeutics in the fourth quarter worth about $80,697,000. Bank of Nova Scotia bought a new position in Sarepta Therapeutics in the fourth quarter worth about $50,990,000. Finally, Avoro Capital Advisors LLC raised its stake in Sarepta Therapeutics by 7.9% in the fourth quarter. Avoro Capital Advisors LLC now owns 4,344,444 shares of the biotechnology company's stock worth $418,935,000 after buying an additional 319,444 shares in the last quarter. 86.68% of the stock is owned by institutional investors.

## Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on SRPT shares. Morgan Stanley reissued an "overweight" rating and set a $165.00 target price on shares of Sarepta Therapeutics in a report on Friday, June 21st. Oppenheimer upgraded shares of Sarepta Therapeutics from a "market perform" rating to an "outperform" rating and set a $180.00 price target for the company in a research report on Tuesday, May 14th. BMO Capital Markets boosted their price target on shares of Sarepta Therapeutics from $170.00 to $200.00 and gave the company an "outperform" rating in a research report on Monday, June 24th. Bank of America boosted their price target on shares of Sarepta Therapeutics from $166.00 to $213.00 and gave the company a "buy" rating in a research report on Friday, June 21st. Finally, Citigroup reduced their price target on shares of Sarepta Therapeutics from $176.00 to $160.00 and set a "neutral" rating for the company in a research report on Thursday, August 8th. Three investment analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $186.22.

  

-   PepGen soars on Sarepta Therapeutics’ Duchenne drug phase 2 data

**Read Our Latest Stock Analysis on Sarepta Therapeutics**

## About Sarepta Therapeutics

(Get Free Report)

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.

## Read More

-   Five stocks we like better than Sarepta Therapeutics
-   How Technical Indicators Can Help You Find Oversold Stocks
-   3 Small Cap Stocks That Insiders Are Buying
-   Which Wall Street Analysts are the Most Accurate?
-   Analysts Forecast Big Upside for Western Digital—Don’t Miss Out
-   3 Small Caps With Big Return Potential
-   3 Must-Own Stocks for Bullish Investors in Today's Market

*This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.*

→ Tim Sykes’ Urgent Trade Alert: “Make this move now” (From Timothy Sykes) (Ad)## Should you invest $1,000 in Sarepta Therapeutics right now?

Before you consider Sarepta Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sarepta Therapeutics wasn't on the list.

While Sarepta Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

### Related Stocks

- [SRPT.US - Sarepta Therap](https://longbridge.com/en/quote/SRPT.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Sarepta 医疗｜8-K：2025 财年 Q4 营收 3.7 亿美元不及预期 |  | [Link](https://longbridge.com/en/news/272301520.md) |
| Sarepta 因获得新西兰监管机构批准开始亨廷顿病试验而股价上涨 | Sarepta Therapeutics 的股票在盘前交易中上涨 3%，至 20.92 美元，此前该公司在新西兰获得了启动 SRP-1005 的人体试验的监管批准，这是一种针对亨廷顿舞蹈症的实验性治疗。该早期试验将招募约 24 名参与者，重 | [Link](https://longbridge.com/en/news/274824082.md) |
| 展望未来：8 位分析师对 Sarepta Therapeutics 的预测 | 在过去三个月中，8 位分析师对 Sarepta Therapeutics（NASDAQ:SRPT）进行了评估，显示出从看涨到看跌的情绪范围。12 个月的平均目标价为 22.25 美元，最高为 45.00 美元，最低为 5.00 美元。最近的 | [Link](https://longbridge.com/en/news/272548848.md) |
| 增长前景放缓和监管风险加剧导致对 Sarepta Therapeutics 的卖出评级 | Needham 分析师 Gil Blum 重申了对 Sarepta Therapeutics (SRPT) 的卖出评级，原因是对其增长前景和监管风险的担忧。尽管 2025 年的收入指引符合预期，但缺乏具体的 2026 年指引引发了对潜在收入 | [Link](https://longbridge.com/en/news/272438221.md) |
| Sarepta 医疗第四季度初步净产品收入未能达到预期 | Sarepta Therapeutics 报告了初步的第四季度净产品收入为 3.696 亿美元，低于分析师预期的 3.8207 亿美元。收入受到严重流感季节和重新安排的输液影响。公司在 2025 年结束时拥有 9.538 亿美元的现金和投资 | [Link](https://longbridge.com/en/news/272301526.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
